Related Experiment Video
Updated: Jul 21, 2025
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
18.3K
Endogenous Opioids in Crohn's Disease
Adrian Martyniak1, Andrzej Wędrychowicz2, Przemysław J Tomasik1
1Department of Clinical Biochemistry, Pediatric Institute, Faculty of Medicine, Jagiellonian University Medical College, 30-663 Krakow, Poland.
Biomedicines
|July 29, 2023
Summary
Adolescents with Crohn
Area of Science:
- Gastroenterology
- Immunology
- Endocrinology
Background:
- Crohn's disease (CD) presents a significant challenge in adolescent medicine.
- Endogenous opioids possess analgesic and anti-inflammatory properties, potentially impacting CD.
- Existing research on endogenous opioids in CD is inconsistent, with limited data on plasma levels.
Purpose of the Study:
- To quantify serum concentrations of human β-endorphin, human proenkephalin (A), and human big dynorphin.
- To assess these levels in adolescent CD patients during acute, treatment, and remission phases.
- To compare levels against a healthy control group.
Main Methods:
- Serum samples collected from adolescent CD patients and healthy controls.
- Enzyme-linked immunosorbent assay (ELISA) kits used for quantification.
- Measurements taken during acute disease, hospital treatment, and remission states.
Main Results:
- Significantly reduced serum concentrations of β-endorphin and proenkephalin (A) found in CD patients.
- Reduced levels observed across acute, treatment, and remission phases compared to controls.
- All tested endogenous opioid levels were lower in adolescents with CD.
Conclusions:
- Endogenous opioid system is modulated in adolescent Crohn's disease.
- Reduced levels of key endogenous opioids suggest a potential role in disease pathogenesis.
- Targeting the endogenous opioid system with nonnarcotic agonists may offer future therapeutic strategies for CD.
More Related Videos
Related Concept Videos
01:22Opioid Receptors: Overview
1.0K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
1.0K
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
247
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
247
01:30Inflammatory Bowel Disease II: Crohn's Disease
293
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
293
01:25Analgesia and Pain Management
660
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
660
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
153
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
153